Cargando…

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects

Palbociclib is a good candidate for therapeutic drug monitoring (TDM) due to its narrow therapeutic range and frequency of toxicities, particularly high-grade neutropenia. In this prospective, bicentric clinical trial, we evaluated the palbociclib exposure–toxicity relationship and determined the re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leenhardt, Fanny, Fiteni, Frédéric, Gauthier, Ludovic, Alexandre, Marie, Guiu, Séverine, Firmin, Nelly, Pouderoux, Stéphane, Viala, Marie, Lossaint, Gerald, Gautier, Chloé, Mollevi, Caroline, Gracia, Matthieu, Gongora, Celine, Mbatchi, Litaty, Evrard, Alexandre, Jacot, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032884/ https://www.ncbi.nlm.nih.gov/pubmed/35456675 http://dx.doi.org/10.3390/pharmaceutics14040841

Ejemplares similares

Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key
por: Thomas, Quentin Dominique, et al.
Publicado: (2023)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer
por: Viala, Marie, et al.
Publicado: (2021)

PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1
por: Matheux, Alice, et al.
Publicado: (2021)

Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021)

Early treatment-related neutropenia predicts response to palbociclib
por: McAndrew, Nicholas P., et al.
Publicado: (2020)

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019)

Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection
por: Viala, Marie, et al.
Publicado: (2018)

Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021)

A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy
por: Chartron, Elodie, et al.
Publicado: (2021)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2021)

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Lee, Yeonhong, et al.
Publicado: (2023)

Efficacy of Limited Dose Modifications for Palbociclib-Related Grade 3 Neutropenia in Hormone Receptor–Positive Metastatic Breast Cancer
por: Kim, Seul-Gi, et al.
Publicado: (2023)

Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study
por: Fabbro, Michel, et al.
Publicado: (2022)

MODL-03. ADAPTING PALBOCICLIB FOR MEDULLOBLASTOMA THERAPY BY IMPROVING DRUG DELIVERY AND ADDRESSING RESISTANCE
por: Dismuke, Taylor, et al.
Publicado: (2020)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
por: Le Louedec, Félicien, et al.
Publicado: (2020)

Idiosyncratic Drug-Induced Neutropenia and Agranulocytosis in Elderly Patients
por: Lorenzo-Villalba, Noel, et al.
Publicado: (2020)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study
por: Dell’Ova, Mélodie, et al.
Publicado: (2015)

Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study
por: Jacot, William, et al.
Publicado: (2010)

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases
por: Darlix, Amélie, et al.
Publicado: (2019)

Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With Neutropenia
por: Haddadi, Pedram, et al.
Publicado: (2014)

Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia
por: Takigawa, Masaki, et al.
Publicado: (2023)

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Cancer-Related Alopecia: From Etiologies to Global Management
por: Quesada, Stanislas, et al.
Publicado: (2021)

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature
por: Beddok, Arnaud, et al.
Publicado: (2020)

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Beechinor, R., et al.
Publicado: (2022)

Multiple drugs: Neutropenia and COVID-19 infection: 4 case reports
Publicado: (2020)

Amiodarone-Induced Neutropenia: An Uncommon Side Effect of a Common Drug
por: Kohli, Akshay, et al.
Publicado: (2020)

The Pattern of Microorganisms and Drug Susceptibility in Pediatric Oncologic Patients with Febrile Neutropenia
por: Jungrungrueng, Thanyathorn, et al.
Publicado: (2021)

Multiple drugs: Neutropenia and off-label use: 3 case reports
Publicado: (2021)

Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016
por: Glocker, Catherine, et al.
Publicado: (2023)

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
por: Hernandez Maganhi, Stella, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_int8fro6j9oa4bu7ifmvqld9s5